rs57605939
Variant summary
Our verdict is Benign. Variant got -13 ACMG points: 0P and 13B. BP4_StrongBP6BA1
The NM_024675.4(PALB2):c.629C>T(p.Pro210Leu) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.00362 in 1,614,072 control chromosomes in the GnomAD database, including 191 homozygotes. In-silico tool predicts a benign outcome for this variant. 12/20 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
Frequency
Consequence
NM_024675.4 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Benign. Variant got -13 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes AF: 0.0193 AC: 2942AN: 152088Hom.: 89 Cov.: 32
GnomAD3 exomes AF: 0.00477 AC: 1199AN: 251404Hom.: 33 AF XY: 0.00364 AC XY: 494AN XY: 135886
GnomAD4 exome AF: 0.00197 AC: 2879AN: 1461864Hom.: 98 Cov.: 33 AF XY: 0.00169 AC XY: 1229AN XY: 727234
GnomAD4 genome AF: 0.0195 AC: 2969AN: 152208Hom.: 93 Cov.: 32 AF XY: 0.0192 AC XY: 1427AN XY: 74424
ClinVar
Submissions by phenotype
not specified Benign:7Other:1
- -
- -
- -
- -
- -
- -
- -
- -
Hereditary cancer-predisposing syndrome Benign:5
- -
- -
- -
This alteration is classified as benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. -
- -
Familial cancer of breast Uncertain:1Benign:3
- -
- -
Curators: Marc Tischkowitz, Arleen D. Auerbach. Submitter to LOVD: Marc Tischkowitz. -
- -
not provided Benign:2
- -
This variant is associated with the following publications: (PMID: 24728327) -
Fanconi anemia complementation group N Benign:1
This variant was observed as part of a predisposition screen in an ostensibly healthy population. A literature search was performed for the gene, cDNA change, and amino acid change (where applicable). No publications were found based on this search. Allele frequency data from public databases was too high to be consistent with this variant causing disease. Therefore, this variant is classified as benign. -
Breast and/or ovarian cancer Benign:1
- -
Malignant tumor of breast Benign:1
The PALB2 p.Pro210Leu variant was identified in 65 of 10554 proband chromosomes (frequency: 0.006) from individuals or families with breast cancer and was present in 37 of 8955 control chromosomes (frequency: 0.0005) from healthy individuals (Rahman_2007_17200668, Garcia_2009_18302019, Ding_2011_21113654, Zheng_2012_21932393, Tischkowitz_2012_22241545, Thompson_2015_26283626). The variant was also identified in the following databases: dbSNP (ID: rs57605939) as “With other allele”, ClinVar (8x, as benign by Invitae, Ambry, EGL Genetic, Color Genomics, Illumina, Pathway Genomics, PALB2 database, 2x as likely benign, by Cancer Genetics, Institute for Biomarker, 1x as uncertain significant by ITMI), Clinvitae (3x as benign and 3x with conflicting interpretations of pathogenicity by ClinVar and EmvClass), LOVD 3.0 (5x). The variant was not identified in Cosmic, MutDB, and Zhejiang Colon Cancer Databases. The variant was identified in control databases in 1750 of 277182 chromosomes (51 homozygous) at a frequency of 0.006 increasing the likelihood this could be a low frequency variant (Genome Aggregation Database Feb 27, 2017). Breakdown of the observations by population include African in 1618 of 24022 chromosomes (freq: 0.07), other in 13 of 6468 chromosomes (freq: 0.002), Latino in 105 of 34420 chromosomes (freq: 0.003), European Non-Finnish in 10 of 126682 chromosomes (freq: 0.00008), Ashkenazi Jewish in 1 of 10152 chromosomes (freq: 0.0001), and South Asian in 3 of 30782 chromosomes (freq: 0.0001), while the variant was not observed in the East Asian, European Finnish, populations. The p.Pro210Leu residue is conserved in mammals and computational analyses (PolyPhen-2, SIFT, AlignGVGD, BLOSUM, MutationTaster) provide inconsistent predictions regarding the impact to the protein; this information is not very predictive of pathogenicity. The variant occurs outside of the splicing consensus sequence and in silico or computational prediction software programs (SpliceSiteFinder, MaxEntScan, NNSPLICE, GeneSplicer, HumanSpliceFinder) do not predict a difference in splicing. In summary, based on the above information this variant meets our laboratory's criteria to be classified as benign. -
Hereditary breast ovarian cancer syndrome Benign:1
- -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at